Literature DB >> 24806974

Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis.

O Beauchet1, C P Launay, G Allali, C Annweiler.   

Abstract

BACKGROUND: Studies have examined the effects of anti-dementia drugs on gait performance. No structured critical evaluation of these studies has been done so far. The objectives of this study were (1) to perform a qualitative analysis of all published studies on changes in stride time variability (STV) with anti-dementia drugs among patients with Alzheimer disease through a systematic review, and (2) to quantitatively synthesize anti-dementia drug-related changes in STV.
METHODS: An English and French MEDLINE search was conducted on November 2013, with no limit of date, using the Medical Subject Headings term "pharmaceutical preparations" combined with "delirium", "dementia", "amnestic", "cognitive disorders" AND "gait" OR "gait disorders, neurologic" OR "gait apraxia". Fixed-effects meta-analyses were performed to compare STV before and after the use of anti-dementia drugs, and to compare the final STV among participants in intervention and control groups.
RESULTS: Of the 110 originally identified abstracts, four studies (i.e., one assessing galantamine, one donepezil, one memantine, and one memantine and acetylcholinesterase inhibitors) were included in the qualitative review, and three studies in the quantitative synthesis. Results were mixed, as two studies showed significant between-visit improvements (i.e., decrease in mean value) in STV, while one study did not, and the last one reported mixed results. In the meta-analysis, there was no difference between intervention and control groups (summary mean difference of final STV = -0.38 % [95 % confidence interval -1.14 to 0.37]) and no before-after difference in the intervention group (summary mean difference of STV = 0.66 [95 % confidence interval -0.17 to 1.49]).
CONCLUSIONS: Our findings showed inconclusive effects of anti-dementia drugs on STV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24806974     DOI: 10.1007/s40263-014-0170-6

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  21 in total

1.  Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls.

Authors:  Manuel Montero-Odasso; Jennie Wells; Michael Borrie
Journal:  J Am Geriatr Soc       Date:  2009-02       Impact factor: 5.562

2.  Galantamine improves gait performance in patients with Alzheimer's disease.

Authors:  Frédéric Assal; Gilles Allali; Reto W Kressig; François R Herrmann; Olivier Beauchet
Journal:  J Am Geriatr Soc       Date:  2008-05       Impact factor: 5.562

3.  Gait variability and fall risk in community-living older adults: a 1-year prospective study.

Authors:  J M Hausdorff; D A Rios; H K Edelberg
Journal:  Arch Phys Med Rehabil       Date:  2001-08       Impact factor: 3.966

4.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  PLoS Med       Date:  2010-03-24       Impact factor: 11.069

5.  Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease.

Authors:  Quincy J Almeida; James S Frank; Eric A Roy; Aftab E Patla; Mandar S Jog
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

Review 6.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

Authors:  Chris G Parsons; Albrecht Stöffler; Wojciech Danysz
Journal:  Neuropharmacology       Date:  2007-08-10       Impact factor: 5.250

Review 7.  Gait and cognition: a complementary approach to understanding brain function and the risk of falling.

Authors:  Manuel Montero-Odasso; Joe Verghese; Olivier Beauchet; Jeffrey M Hausdorff
Journal:  J Am Geriatr Soc       Date:  2012-10-30       Impact factor: 5.562

8.  Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial.

Authors:  Manuel Montero-Odasso; Jennie L Wells; Michael J Borrie; Mark Speechley
Journal:  BMC Neurol       Date:  2009-08-12       Impact factor: 2.474

Review 9.  Rivastigmine in the treatment of Alzheimer's disease: an update.

Authors:  Maria Luisa Onor; Marianna Trevisiol; Eugenio Aguglia
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  Gait analysis in demented subjects: Interests and perspectives.

Authors:  Olivier Beauchet; Gilles Allali; Gilles Berrut; Caroline Hommet; Véronique Dubost; Frédéric Assal
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

View more
  5 in total

Review 1.  Management of Gait Changes and Fall Risk in MCI and Dementia.

Authors:  Gilles Allali; Joe Verghese
Journal:  Curr Treat Options Neurol       Date:  2017-09       Impact factor: 3.598

2.  Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial.

Authors:  Olivier Beauchet; John Barden; Teresa Liu-Ambrose; Victoria L Chester; Cedric Annweiler; Tony Szturm; Sébastien Grenier; Guillaume Léonard; Louis Bherer; Gilles Allali
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

3.  Aging, the Central Nervous System, and Mobility in Older Adults: Interventions.

Authors:  Vijay R Varma; Jeffrey M Hausdorff; Stephanie A Studenski; Caterina Rosano; Richard Camicioli; Neil B Alexander; Wen G Chen; Lewis A Lipsitz; Michelle C Carlson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-05-06       Impact factor: 6.053

Review 4.  Motoric Cognitive Risk Syndrome: Symptoms, Pathology, Diagnosis, and Recovery.

Authors:  Ke Xiang; Yin Liu; Li Sun
Journal:  Front Aging Neurosci       Date:  2022-02-02       Impact factor: 5.750

5.  Polyphenols Derived from Lychee Seed Suppress Aβ (1-42)-Induced Neuroinflammation.

Authors:  Yong Tang; Rui Xiong; An-Guo Wu; Chong-Lin Yu; Ya Zhao; Wen-Qiao Qiu; Xiu-Ling Wang; Jin-Feng Teng; Jian Liu; Hai-Xia Chen; Jian-Ming Wu; Da-Lian Qin
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.